141 related articles for article (PubMed ID: 36136021)
21. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.
Moreno C; Montillo M; Panayiotidis P; Dimou M; Bloor A; Dupuis J; Schuh A; Norin S; Geisler C; Hillmen P; Doubek M; Trněný M; Obrtlikova P; Laurenti L; Stilgenbauer S; Smolej L; Ghia P; Cymbalista F; Jaeger U; Stamatopoulos K; Stavroyianni N; Carrington P; Zouabi H; Leblond V; Gomez-Garcia JC; Rubio M; Marasca R; Musuraca G; Rigacci L; Farina L; Paolini R; Pospisilova S; Kimby E; Bradley C; Montserrat E
Haematologica; 2015 Apr; 100(4):511-6. PubMed ID: 25596264
[TBL] [Abstract][Full Text] [Related]
22. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
[TBL] [Abstract][Full Text] [Related]
23. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
[No Abstract] [Full Text] [Related]
24. Ofatumumab in the treatment of chronic lymphocytic leukemia.
Tsimberidou AM
Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.
Davids MS; Kuss BJ; Hillmen P; Montillo M; Moreno C; Essell J; Lamanna N; Nagy Z; Tam CS; Stilgenbauer S; Ghia P; Delgado J; Lustgarten S; Weaver DT; Youssoufian H; Jäger U
Clin Cancer Res; 2020 May; 26(9):2096-2103. PubMed ID: 31964785
[TBL] [Abstract][Full Text] [Related]
26. Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.
Dupuis J; Brice P; François S; Ysebaert L; de Guibert S; Levy V; Leprêtre S; Choquet S; Dilhuydy MS; Fornecker L; Morel V; Tempescul A
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):e43-6. PubMed ID: 25193089
[TBL] [Abstract][Full Text] [Related]
27. Obinutuzumab breaks through to FDA approval.
Cancer Discov; 2014 Jan; 4(1):OF6. PubMed ID: 24402958
[TBL] [Abstract][Full Text] [Related]
28. Duvelisib in haematological malignancies.
Das M
Lancet Oncol; 2018 Nov; 19(11):e586. PubMed ID: 30318318
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
30. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
van Oers MH; Kuliczkowski K; Smolej L; Petrini M; Offner F; Grosicki S; Levin MD; Gupta I; Phillips J; Williams V; Manson S; Lisby S; Geisler C;
Lancet Oncol; 2015 Oct; 16(13):1370-9. PubMed ID: 26377300
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab (Arzerra) for CLL.
Med Lett Drugs Ther; 2010 Jun; 52(1341):51-2. PubMed ID: 20585286
[No Abstract] [Full Text] [Related]
32. Berlex Laboratories to market new treatment for B-CLL.
Expert Rev Anticancer Ther; 2001 Jun; 1(1):3. PubMed ID: 12113127
[No Abstract] [Full Text] [Related]
33. Ofatumumab: chronic lymphocytic leukaemia: a last resort.
Prescrire Int; 2010 Oct; 19(109):201-3. PubMed ID: 21180369
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
[TBL] [Abstract][Full Text] [Related]
35. FDA: Increased HBV reactivation risk with ofatumumab or rituximab.
Mitka M
JAMA; 2013 Oct; 310(16):1664. PubMed ID: 24150447
[No Abstract] [Full Text] [Related]
36. Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard?
Goodman M
J Clin Oncol; 2005 Oct; 23(28):7240-1; author reply 7241-2. PubMed ID: 16192616
[No Abstract] [Full Text] [Related]
37. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB
Pediatr Blood Cancer; 2023 Aug; 70(8):e30398. PubMed ID: 37140091
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Hadj Tahar A
Issues Emerg Health Technol; 2005 Mar; (66):1-4. PubMed ID: 15806747
[TBL] [Abstract][Full Text] [Related]
39. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Bello C; Veliz M; Pinilla-Ibarz J
Expert Rev Clin Immunol; 2011 May; 7(3):295-300. PubMed ID: 21595596
[TBL] [Abstract][Full Text] [Related]
40. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia.
Small S
Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
